What is your approach between choosing lumasiran or nedosiran for patients with primary hyperoxaluria type 1?

At this time, the available evidence suggests both agents are more or less equally effective for PH1 in reducing urinary oxalate excretion over many months. Thus I would be comfortable prescribing either for a PH1 patient.

Great answer about a challenging question about therapeutic options with primary hyperoxaluria.